. . . . "\u7D04\u7FF0\u00B7\u66FC\u5FB7\u68EE (\u91AB\u5B78\u5BB6)"@zh . . . . . . . "John Mendelsohn (Mediziner)"@de . . . "\u0414\u0436\u043E\u043D \u041C\u0435\u043D\u0434\u0435\u043B\u044C\u0441\u043E\u043D (John Mendelsohn; 31 \u0430\u0432\u0433\u0443\u0441\u0442\u0430 1936 \u2014 7 \u044F\u043D\u0432\u0430\u0440\u044F 2019) \u2014 \u0430\u043C\u0435\u0440\u0438\u043A\u0430\u043D\u0441\u043A\u0438\u0439 \u043E\u043D\u043A\u043E\u043B\u043E\u0433.\u0421\u043E\u0442\u0440\u0443\u0434\u043D\u0438\u043A MD Anderson Cancer Center, \u0447\u043B\u0435\u043D \u041D\u0430\u0446\u0438\u043E\u043D\u0430\u043B\u044C\u043D\u043E\u0439 \u043C\u0435\u0434\u0438\u0446\u0438\u043D\u0441\u043A\u043E\u0439 \u0430\u043A\u0430\u0434\u0435\u043C\u0438\u0438 \u0421\u0428\u0410 (1997) \u0438 \u041D\u0438\u0434\u0435\u0440\u043B\u0430\u043D\u0434\u0441\u043A\u043E\u0439 \u043A\u043E\u0440\u043E\u043B\u0435\u0432\u0441\u043A\u043E\u0439 \u0430\u043A\u0430\u0434\u0435\u043C\u0438\u0438 \u043D\u0430\u0443\u043A (1999).\u0420\u0430\u0437\u0440\u0430\u0431\u043E\u0442\u0447\u0438\u043A \u0446\u0435\u0442\u0443\u043A\u0441\u0438\u043C\u0430\u0431\u0430."@ru . . . . . . . "31049529"^^ . . . . . . . . . . . . . . "\u7D04\u7FF0\u00B7\u66FC\u5FB7\u68EE\uFF08\u82F1\u8A9E\uFF1AJohn Mendelsohn\uFF0C1936\u5E748\u670831\u65E5\uFF0D2019\u5E741\u67087\u65E5)\uFF0C\u7814\u767C\u51FA\u7B2C\u4E00\u7A2E\u6A19\u9776\u85E5\u7269Erbitux\uFF08\u723E\u5FC5\u5F97\u8212\uFF09\u7684\u91AB\u5B78\u5BB6\u3002\u548C\u6771\u5C3C\u00B7\u676D\u7279\uFF08Tony Hunter\uFF09\u3001\u5E03\u840A\u6069\u00B7\u5FB7\u9B6F\u514B\u723E\uFF08Brian J. Druker\uFF09\u4E00\u540C\u7372\u5F972018\u5E74\u5510\u734E\u751F\u6280\u91AB\u85E5\u734E\u30022019\u5E741\u67087\u65E5\u56E0\u8166\u764C\u53BB\u4E16\u3002"@zh . . "\u041C\u0435\u043D\u0434\u0435\u043B\u044C\u0441\u043E\u043D, \u0414\u0436\u043E\u043D"@ru . . . . . . "Cornell University Medical College"@en . . . . . . . . . . . . . . "\u0414\u0436\u043E\u043D \u041C\u0435\u043D\u0434\u0435\u043B\u044C\u0441\u043E\u043D (John Mendelsohn; 31 \u0430\u0432\u0433\u0443\u0441\u0442\u0430 1936 \u2014 7 \u044F\u043D\u0432\u0430\u0440\u044F 2019) \u2014 \u0430\u043C\u0435\u0440\u0438\u043A\u0430\u043D\u0441\u043A\u0438\u0439 \u043E\u043D\u043A\u043E\u043B\u043E\u0433.\u0421\u043E\u0442\u0440\u0443\u0434\u043D\u0438\u043A MD Anderson Cancer Center, \u0447\u043B\u0435\u043D \u041D\u0430\u0446\u0438\u043E\u043D\u0430\u043B\u044C\u043D\u043E\u0439 \u043C\u0435\u0434\u0438\u0446\u0438\u043D\u0441\u043A\u043E\u0439 \u0430\u043A\u0430\u0434\u0435\u043C\u0438\u0438 \u0421\u0428\u0410 (1997) \u0438 \u041D\u0438\u0434\u0435\u0440\u043B\u0430\u043D\u0434\u0441\u043A\u043E\u0439 \u043A\u043E\u0440\u043E\u043B\u0435\u0432\u0441\u043A\u043E\u0439 \u0430\u043A\u0430\u0434\u0435\u043C\u0438\u0438 \u043D\u0430\u0443\u043A (1999).\u0420\u0430\u0437\u0440\u0430\u0431\u043E\u0442\u0447\u0438\u043A \u0446\u0435\u0442\u0443\u043A\u0441\u0438\u043C\u0430\u0431\u0430."@ru . . . . . . "Houston, Texas, U.S."@en . . . . "2019-01-07"^^ . "MD Anderson Cancer Center"@en . . . . . . . . . . . . . . . . . . "Harvard University"@en . . . "John Mendelsohn (doctor)"@en . "Memorial Sloan Kettering Cancer Center"@en . . "John Mendelsohn (August 31, 1936 \u2013 January 7, 2019) was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research. Mendelsohn served as MD Anderson president from 1996 to 2011. When Ronald DePinho became president, he stepped down September 1, 2011. Mendelsohn remained on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Also, he was a senior fellow in health and technology at the Baker Institute."@en . . ""@en . . . . . "Cincinnati, Ohio, U.S."@en . "1109564934"^^ . . . . . . "2019-01-07"^^ . . . "Baker Institute"@en . . . . "11319"^^ . . . "John Mendelsohn (August 31, 1936 \u2013 January 7, 2019) was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research. Mendelsohn served as MD Anderson president from 1996 to 2011. When Ronald DePinho became president, he stepped down September 1, 2011. Mendelsohn remained on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Also, he was a senior fellow in health and technology at the Baker Institute. Mendelsohn was only the third full-time president of MD Anderson. When he arrived, Mendelsohn's focus shifted from his expertise in laboratory research and clinical trials to leading an institution that employs about 18,000 people and serves 100,000 patients yearly, with a budget of more than $3.3 billion."@en . . . . . . "University of California, San Diego"@en . "John Mendelsohn (* 31. August 1936 in Cincinnati, Ohio; \u2020 7. Januar 2019) war ein US-amerikanischer Onkologe am University of Texas MD Anderson Cancer Center in Houston, Texas. Er machte sich um die klinische Entwicklung von Cetuximab verdient, ein therapeutischer chim\u00E4rer monoklonaler Antik\u00F6rper vom Typ IgG1 gegen den Epidermalen Wachstumsfaktor-Rezeptor (EGFR), der in der Onkologie (Krebsmedizin) zur Krebsimmuntherapie eingesetzt wird."@de . . . . ""@en . . . "1936-08-31"^^ . . . . . . . . . . . . . . "1936-08-31"^^ . "\u7D04\u7FF0\u00B7\u66FC\u5FB7\u68EE\uFF08\u82F1\u8A9E\uFF1AJohn Mendelsohn\uFF0C1936\u5E748\u670831\u65E5\uFF0D2019\u5E741\u67087\u65E5)\uFF0C\u7814\u767C\u51FA\u7B2C\u4E00\u7A2E\u6A19\u9776\u85E5\u7269Erbitux\uFF08\u723E\u5FC5\u5F97\u8212\uFF09\u7684\u91AB\u5B78\u5BB6\u3002\u548C\u6771\u5C3C\u00B7\u676D\u7279\uFF08Tony Hunter\uFF09\u3001\u5E03\u840A\u6069\u00B7\u5FB7\u9B6F\u514B\u723E\uFF08Brian J. Druker\uFF09\u4E00\u540C\u7372\u5F972018\u5E74\u5510\u734E\u751F\u6280\u91AB\u85E5\u734E\u30022019\u5E741\u67087\u65E5\u56E0\u8166\u764C\u53BB\u4E16\u3002"@zh . . . "John Mendelsohn (* 31. August 1936 in Cincinnati, Ohio; \u2020 7. Januar 2019) war ein US-amerikanischer Onkologe am University of Texas MD Anderson Cancer Center in Houston, Texas. Er machte sich um die klinische Entwicklung von Cetuximab verdient, ein therapeutischer chim\u00E4rer monoklonaler Antik\u00F6rper vom Typ IgG1 gegen den Epidermalen Wachstumsfaktor-Rezeptor (EGFR), der in der Onkologie (Krebsmedizin) zur Krebsimmuntherapie eingesetzt wird. Mendelsohn erwarb 1958 an der Harvard University einen Bachelor in Biochemie und 1963 an der Harvard Medical School einen M.D. als Abschluss des Medizinstudiums. Akademische Stationen (Professuren) waren die University of California, San Diego (1970\u20131985), Cornell University und Sloan-Kettering Institute for Cancer Research (1985\u20131996) und University of Texas MD Anderson Cancer Center (ab 1996)."@de . . .